MAP Pharmaceuticals Reports Second Quarter of 2009 Financi...(372 805 ...),Health

Date:8/3/2009

372 805 --- --- Total current assets 60,300 45,515 Property and equipment, net 4,457 5,007 Other assets 28 28 Restricted cash 310 310 --- --- Total assets $65,095 $50,860 ======= ======= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $12,709 $17,076 Current portion of debt 7,025 6,348 Current portion of deferred revenue 16,552 - ------ ------ Total current liabilities 36,286 23,424 Debt, less current portion 10,890 14,229 Deferred revenue, less current portion 16,552 - Other liabilities 74 60 -- -- Total liabilities 63,802 37,713 Total stockholders' equity 1,293 13,147 ----- ------ Total liabilities and stockholders' equity $65,095 $50,860 ======= ======= MAP PHARMACEUTICALS, INC. (a development stage enterprise) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIO
'/>"/>

SOURCE MAP Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals